Dennis Trieu
Family Medicine · Los Angeles, CANPI 1245862887
Payments from drug & device makers
Across 732 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- AbbVie$2K
- Amgen$2K
- Gilead$1K
- Bayer$1K
- plus $10K from 39 others
What the payments were for
- Food & beverage$20,793100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,807 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 210 | $135,248 |
| VascepaIcosapent Ethyl | 317 | $90,579 |
| LinzessLinaclotide | 160 | $86,655 |
| RybelsusSemaglutide | 82 | $82,859 |
| CreonLipase/Protease/Amylase | 66 | $81,354 |
| JanuviaSitagliptin Phosphate | 138 | $78,341 |
| JardianceEmpagliflozin | 97 | $61,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $61,092 |
| EliquisApixaban | 83 | $52,051 |
| KerendiaFinerenone | 65 | $42,511 |
| VemlidyTenofovir Alafenamide | 27 | $38,898 |
| TradjentaLinagliptin | 81 | $36,369 |
| ZenpepLipase/Protease/Amylase | 24 | $32,043 |
| OzempicSemaglutide | 27 | $29,241 |
| ProliaDenosumab | 16 | $26,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Airsupra | $3,444 | $174,875291 claims |
| AbbVieLinzess, Creon | $1,772 | $168,009226 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Jentadueto | $1,013 | $136,039254 claims |
| Novo NordiskRybelsus, Ozempic | $1,135 | $112,100109 claims |
| MerckJanuvia, Janumet, Janumet Xr | $168 | $107,846198 claims |
| GSKTrelegy Ellipta | $1,804 | $61,092100 claims |
| PfizerEliquis | $258 | $52,05183 claims |
| BayerKerendia | $1,160 | $42,51165 claims |
| GileadVemlidy | $1,427 | $38,89827 claims |
| Aimmune Therapeutics, Inc.Zenpep | $268 | $32,04324 claims |
| AmgenProlia | $1,571 | $26,37316 claims |
| Esperion Therapeutics, Inc.Nexletol | $379 | $16,14842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.